Skip to main content

NATCO Pharma Limited (NATCOPHARM.BO)

Bombay Stock Exchange (India) Healthcare Drug Manufacturers - Specialty & GenericView data quality →
68.4Fair

ValueMarkers Composite Index

Top 98%#714 of 44,707
Undervalued

72% below intrinsic value ($46)

UndervaluedFair ValueOvervalued
Piotroski
6/9
Neutral
Beneish
-2.98
Low Risk
Altman
14.92
Safe
DCF Value
$46
Undervalued
ROIC
16.9%
Strong
P/E
12.4
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

NATCO Pharma Limited (NATCOPHARM.BO) — VMCI valuation read

NATCOPHARM.BO screens at VMCI 68/100, a 18-point gap above the Healthcare sector median (50). For a mid-cap NATCO Pharma Limited share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.

NATCOPHARM.BO has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: NATCOPHARM.BO trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 1.0x leaves covenant headroom, which sets the rate-cycle exposure for NATCO Pharma Limited.

NATCOPHARM.BO fell 0.4% over the trailing 7 days, with a -8.0% read on a 30-day basis.

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. It markets its products in approximately 50 countries. The company was incorporated in 1981 and is headquartered in Hyderabad, India.

CEO: Rajeev Nannapaneni4,016 employeesINwww.natcopharma.co.in

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in NATCOPHARM.BO’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.